Stocks Under $1: NXXT, TOON, VRAX, AIM, SBFM on Breakout Watch

Investors searching for stocks under $1 with breakout potential, AI exposure, biotech catalysts, streaming growth, and emerging healthcare innovation are increasingly focusing on a group of small-cap companies gaining momentum across multiple high-growth sectors. Companies drawing attention include Kartoon Studios (NYSE: TOON), Virax Biolabs Ltd (NASDAQ: VRAX), NextNRG Inc. (NASDAQ: NXXT), AIM ImmunoTech Inc. (NYSE: AIM), and Sunshine Biopharma Inc. (NASDAQ: SBFM).

NextNRG (NASDAQ: NXXT) is gaining visibility after reporting 29% revenue growth and exceeding Wall Street expectations in Q1. The company integrates artificial intelligence (AI) and machine learning (ML) into utility infrastructure, battery storage, renewable energy, wireless EV charging, and mobile fuel delivery through its proprietary Next Utility Operating System Registered . Its smart microgrid and fleet electrification initiatives continue aligning with growing demand for energy modernization, AI-powered infrastructure, and decarbonization solutions.

Kartoon Studios (NYSE: TOON) continues expanding its intellectual property and streaming ecosystem after securing licensing rights to Mattel (NASDAQ: MAT) brands Masters of the Universe and American Girl for Kartoon Channel!. The company reported Q1 2026 distribution revenue growth of 15% year-over-year, while subscriber engagement surged more than 80% on Kartoon Channel! and over 200% on Ameba. Operating expenses declined 20%, contributing to improved operating performance as TOON advances its transition toward higher-margin IP monetization across streaming, licensing, merchandising, and consumer products.

Virax Biolabs (NASDAQ: VRAX) continues positioning itself within the growing immune diagnostics and Long COVID market, developing T cell-based technologies focused on viral disease detection and immunology profiling. The company's platform is designed to support the diagnosis and therapeutic monitoring of post-acute infection syndromes, including Long COVID and other chronic immune-related conditions, areas receiving increasing global healthcare attention.

AIM ImmunoTech (NYSE: AIM) is drawing investor interest following a virtual investor presentation highlighting breakthrough data involving Ampligen Registered for late-stage pancreatic cancer. The company's lead immunotherapy candidate is being advanced as a potential treatment for one of the world's most aggressive cancers, while its selective TLR3 agonist platform continues positioning AIM within the expanding immuno-oncology and precision medicine sector.

Meanwhile, Sunshine Biopharma (NASDAQ: SBFM) continues expanding its pharmaceutical footprint with 71 marketed generic prescription drugs in Canada and 12 additional launches planned through 2026. The company is also advancing proprietary therapeutic programs, including an mRNA-Lipid Nanoparticle candidate targeting liver cancer and a protease inhibitor focused on SARS-related coronavirus infections, strengthening its exposure to both oncology and antiviral drug development markets.

As capital continues rotating into high-growth small-cap sectors, TOON, VRAX, NXXT, AIM, and SBFM are emerging on investor watchlists due to their combination of AI integration, healthcare innovation, streaming growth, renewable energy infrastructure, and biotech catalysts.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stocks-under-1-nxxt-toon-vrax-aim-sbfm-on-breakout-watch]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.